# clinical - LLM run 003

- Script: `llm-test/clinical-llm.py`
- Exit code: `0`
- Rate limit encountered: `yes`
- Fatal rate-limit failure: `no`

## Terminal Output

```text
Waiting 5 seconds for rate limit to cool down...

======================================================================
ANSWER
======================================================================
Backend: groq
Model:   llama-3.3-70b-versatile
To answer the provided questions based on the given `context` and according to the specified guidelines, we will proceed as instructed.

### Step 1: Read `context` and Identify Relevant Information
The `context` contains a clinical trial record document with various sections, including patient records, trial updates, and safety reviews. We will identify the relevant information for each question.

### Step 2: Answer Each Question in `question`
#### Q1: Allergy Flag for PT-2247
The allergy flag currently recorded for subject PT-2247 is PCN-HIGH.

#### Q2: Allergy Flag for PT-2247 (Enrolled Subject Record)
The allergy flag for the enrolled subject record PT-2247, not the screening record, is PCN-HIGH.

#### Q3: Current Allergy Flag for PT-2247
The current allergy flag in the enrolled subject record for PT-2247, as it appears in the main patient record, is PCN-HIGH.

#### Q4: Sentence Explaining Why PT-2247 is Flagged for Enhanced Renal Monitoring
The exact sentence from the document that explains why PT-2247 is flagged for enhanced renal monitoring is:
"Note: Subject PT-2247 is flagged for enhanced renal monitoring due to creatinine trending above threshold at Week 12 visit (1.61 mg/dL)."

#### Q5: Ongoing Protocol Action for PT-2247
To determine the ongoing protocol action for PT-2247:
1. **Drug and Dose**: PT-2247 is receiving Compound VX-7 (high dose, 80mg).
2. **Phase I Safety Review Committee Recommendation**: For subjects in the high-dose cohort, the committee recommended continued monitoring of renal function markers.
Therefore, the ongoing protocol action that should apply to PT-2247 is continued monitoring of renal function markers, as recommended by the Phase I safety review committee for subjects in the high-dose (80mg) cohort of Compound VX-7.

### Step 3: Compile Final Answers
Now, let's compile the final answers into the required format.

```python
final_answer = """
Q1: PCN-HIGH
Q2: PCN-HIGH
Q3: PCN-HIGH
Q4: Note: Subject PT-2247 is flagged for enhanced renal monitoring due to creatinine trending above threshold at Week 12 visit (1.61 mg/dL).
Q5: PT-2247 is receiving Compound VX-7 (high dose, 80mg). The Phase I safety review committee recommended continued monitoring of renal function markers for subjects in the high-dose cohort. Therefore, PT-2247 should undergo continued monitoring of renal function markers as part of the ongoing protocol action.
"""
print(final_answer)
```

======================================================================
LATENCY BREAKDOWN
======================================================================
  Total wall time:    5.877s

======================================================================
TOKEN USAGE
======================================================================
llama-3.3-70b-versatile: input=1,554, output=570, calls=1
======================================================================
```
